Open access · CC-BY
via OpenAlex
Blood-based biomarkers for Alzheimer's disease: Advances in early detection and monitoring of age-related neurodegeneration
Ageing Research Reviews · 2026 · ▲ 17 citations
Abstract
Alzheimer's disease (AD) presents a critical global challenge, accounting for over 60% of the 57 million current dementia cases worldwide, with prevalence projected to exceed 100 million by 2050. Traditional diagnostic approaches, such as cerebrospinal fluid (CSF) analysis and neuroimaging are constrained by invasiveness, high costs, and limited accessibility, particularly problematic in aging population where early detection is crucial for effective intervention. This review synthesizes recent advances in blood-based biomarkers for AD, specifically phosphorylated tau proteins (p-tau217, p-tau181), neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), and the amyloid-β42/40 ratio. These minimally invasive biomarkers demonstrate exceptional diagnostic accuracy with p-tau217 achieving AUC values greater 0.93 and 91% positive predictive value in detecting AD pathology, Critically, these biomarkers can identify pathological changes 15-20 years before symptom onset, with plasma p-tau217 levels increasing over 8.5% annually during preclinical stages. We propose that dried blood spots (DBS), containing both arterial and venous blood components, offer superior representation of brain-derived substances at their first systematic distribution after cardiac output. Ultrasensitive technologies like Simoa and mass spectrometry now enable femtomolar-level detection, revolutionizing of AD diagnostics. However, challenges persist in assay standardization persist in assay standardization, and population-specific validation. Overcoming these barriers to integrate blood biomarkers with DBS technology represents a transformative shift toward accessible, scalable screening in aging communities, offering a paradigm shift in preventing age-related neurodegeneration through early detection and timely intervention. • p-tau217 is the most accurate blood biomarker for AD, with AUCs up to 0.96 and strong correlation with CSF and PET. • Multimarker panels (p-tau217, GFAP, NfL, Aβ42/40) enhance diagnostic accuracy to AUC ~0.97. • DBS and point-of-care tests enable remote, low-cost AD screening but need improvement in Aβ42/40 detection. • Advanced platforms like Simoa and MS allow ultrasensitive detection but lack standardization and remain costly. • Confounding factors (e.g., hematocrit, renal function, assay variability) limit broad clinical implementation.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1016/j.arr.2026.103058
- Canonical
- link ↗
- Fetched
- 2026-10-16 MST
Cite this
APA
Fu, W., & Ho, P.C. (2026). Blood-based biomarkers for Alzheimer's disease: Advances in early detection and monitoring of age-related neurodegeneration. <em>Ageing Research Reviews</em>. https://doi.org/10.1016/j.arr.2026.103058
Vancouver
Fu W, Ho PC. Blood-based biomarkers for Alzheimer's disease: Advances in early detection and monitoring of age-related neurodegeneration. Ageing Research Reviews. 2026. doi:10.1016/j.arr.2026.103058.
BibTeX
@article{wenting2026Bloodb,
title = {Blood-based biomarkers for Alzheimer's disease: Advances in early detection and monitoring of age-related neurodegeneration},
author = {Wenting Fu and Paul C. Ho},
journal = {Ageing Research Reviews},
year = {2026},
doi = {10.1016/j.arr.2026.103058},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Qatar Foundation Annual Research Conference (ARC) 2016
Citation only
Alpha-Synuclein Oligomers as a Biomarker Candidate for Parkinson's Disease and Disorders
EMBO Molecular Medicine 2021
Open access · OA
Blood‐based biomarkers for Alzheimer's disease
Aging and Disease 2024
Open access · CC-BY
Association of Plasma Markers of Alzheimer’s Disease, Neurodegeneration, and Neuroinflammation with the Choroid Plexus Integrity in Aging
Journal of Proteome Research 2026
Open access · CC-BY
Deep Plasma Proteomics-Based Diagnostic Panel for Early Detection of Amnestic Mild Cognitive Impairment
IEEE International Conference on Nanotechnology (IEEE-NANO) 2025
Citation only
Early Diagnostic of Parkinson's Disease by Nano Detection of the Biomarker Alpha-Synuclein
Neuropathology and Applied Neurobiology 2018
Open access · CC-BY